Neurogene to Sell Shares in Secondary Offering

Dow Jones07-01

Neurogene filed to sell shares in a public offering.

The clinical-stage biotechnology company didn't specify how many shares it plans to sell or at what price, according to a filing with the Securities and Exchange Commission on Tuesday. Some investors may receive pre-funded warrants instead of common stock, and underwriters are expected to have a 30-day option to buy additional shares.

Shares declined 4.6% to $30 in post-market trading following disclosure of the company's plan. The stock was off by 2.6% to close the regular trading session at $31.45. Through the close the stock is up 53% this year.

Neurogene said it intends to use proceeds from the sale to fund clinical development and pre-commercial activities for NGN-401, working capital and other general corporate purposes.

NGN-401 is an investigational gene therapy being developed for use as a one-time treatment for Rett syndrome, a rare genetic neurodevelopmental disorder that affects 1 put of every 10,000 live female births in the world.

The company earlier this year reported a first-quarter loss of $30.9 million, or $1.39 per share, compared with a loss of $22.6 million, or $1.08 per share, a year earlier.

Write to Doc Louallen at Doc.Louallen@wsj.com

(END) Dow Jones Newswires

June 30, 2026 16:52 ET (20:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648562189?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 04:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648562189","market":"other","top_or_hot":-1,"title":"Neurogene to Sell Shares in Secondary Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Neurogene filed to sell shares in a public offering. \n</p>\n<p>\n  The clinical-stage biotechnology company didn't specify how many shares it plans to sell or at what price, according to a filing with the Securities and Exchange Commission on Tuesday. Some investors may receive pre-funded warrants instead of common stock, and underwriters are expected to have a 30-day option to buy additional shares. \n</p>\n<p>\n  Shares declined 4.6% to $30 in post-market trading following disclosure of the company's plan. The stock was off by 2.6% to close the regular trading session at $31.45. Through the close the stock is up 53% this year. \n</p>\n<p>\n  Neurogene said it intends to use proceeds from the sale to fund clinical development and pre-commercial activities for NGN-401, working capital and other general corporate purposes. \n</p>\n<p>\n  NGN-401 is an investigational gene therapy being developed for use as a one-time treatment for Rett syndrome, a rare genetic neurodevelopmental disorder that affects 1 put of every 10,000 live female births in the world. \n</p>\n<p>\n  The company earlier this year reported a first-quarter loss of $30.9 million, or $1.39 per share, compared with a loss of $22.6 million, or $1.08 per share, a year earlier. \n</p>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 16:52 ET (20:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurogene to Sell Shares in Secondary Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurogene to Sell Shares in Secondary Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-01 04:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Neurogene filed to sell shares in a public offering. \n</p>\n<p>\n  The clinical-stage biotechnology company didn't specify how many shares it plans to sell or at what price, according to a filing with the Securities and Exchange Commission on Tuesday. Some investors may receive pre-funded warrants instead of common stock, and underwriters are expected to have a 30-day option to buy additional shares. \n</p>\n<p>\n  Shares declined 4.6% to $30 in post-market trading following disclosure of the company's plan. The stock was off by 2.6% to close the regular trading session at $31.45. Through the close the stock is up 53% this year. \n</p>\n<p>\n  Neurogene said it intends to use proceeds from the sale to fund clinical development and pre-commercial activities for NGN-401, working capital and other general corporate purposes. \n</p>\n<p>\n  NGN-401 is an investigational gene therapy being developed for use as a one-time treatment for Rett syndrome, a rare genetic neurodevelopmental disorder that affects 1 put of every 10,000 live female births in the world. \n</p>\n<p>\n  The company earlier this year reported a first-quarter loss of $30.9 million, or $1.39 per share, compared with a loss of $22.6 million, or $1.08 per share, a year earlier. \n</p>\n<p>\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 16:52 ET (20:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NGNE","symbol_name":"NEUROGENE INC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2648562189","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648562189","pubTimestamp":1782852720,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Neurogene filed to sell shares in a public offering.The clinical-stage biotechnology company didn't specify how many shares it plans to sell or at what price, according to a filing with the Securities","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NGNE":"NEUROGENE INC","BK4139":"生物科技"},"translate_title":"Neurogene将在二次发行中出售股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGNE":0.9},"content_text":"Neurogene filed to sell shares in a public offering. \n\n\n  The clinical-stage biotechnology company didn't specify how many shares it plans to sell or at what price, according to a filing with the Securities and Exchange Commission on Tuesday. Some investors may receive pre-funded warrants instead of common stock, and underwriters are expected to have a 30-day option to buy additional shares. \n\n\n  Shares declined 4.6% to $30 in post-market trading following disclosure of the company's plan. The stock was off by 2.6% to close the regular trading session at $31.45. Through the close the stock is up 53% this year. \n\n\n  Neurogene said it intends to use proceeds from the sale to fund clinical development and pre-commercial activities for NGN-401, working capital and other general corporate purposes. \n\n\n  NGN-401 is an investigational gene therapy being developed for use as a one-time treatment for Rett syndrome, a rare genetic neurodevelopmental disorder that affects 1 put of every 10,000 live female births in the world. \n\n\n  The company earlier this year reported a first-quarter loss of $30.9 million, or $1.39 per share, compared with a loss of $22.6 million, or $1.08 per share, a year earlier. \n\n\n  Write to Doc Louallen at Doc.Louallen@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 30, 2026 16:52 ET (20:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648562189","isCrawlerRequest":true}